Drug Therapy

Drugs are approved in the U.S. by the Food and Drug Administration (FDA) for specific purposes to help guide medical practice.

Provider Topics

Anemia/ Iron Deficiency
Brain
Clinicians First Time Seeing a Patient with HHT
Drug Therapy
Gastrointestinal
Genetics
Heart
HHT in children
Insurance
International Guidelines for Screening and Treatment
Liver
Lungs
Nosebleeds or Epistaxis
Pregnancy & Women’s Issues
Skin
Useful Links to Outside Organizations

Advanced Search

Filter by Resource Type

Related Resources

Abstracts – 14th HHT International Scientific Conference (2022)

Scientific Literature – 2023

Angiogenesis. This article is open access and free for a certain period of time; otherwise, it is available for purchase directly from the publisher. Click to view resource.

Executive Summary – 14th HHT International Scientific Conference (2022)

Scientific Literature – 2023

Angiogenesis. This article is open access and free for a certain period of time; otherwise it is available for purchase directly from the publisher. Click to view resource.

Bedside to Bench: How the HHT Community Drives Research Initiatives (Recorded)

Webinar – 2021

In March 2020, Cure HHT was 1 of 30 organizations selected to participate in the Chan Zuckerberg Initiative (also known as CZI) Rare is One Project. This ambitious project is lifting up the work that patient communities are doing to accelerate resear…

Nuts and Bolts of A Clinical Trial – the PATH-HHT Study (Recorded)

Webinar – 2021

Research is the key to the future health and quality of life for HHT patients. “Diseases can only be cured when scientists understand them. This understanding, which comes from basic research, leads to new drugs and treatments.” ~Dr. Christopher Hugh…

International HHT Guidelines – Overview (Recorded)

Webinar – 2021

Join Dr. Marie Faughnan, Director, Toronto HHT Centre of Excellence as she provides an overview of the newly updated International HHT Guidelines and how they are used to set the standard of care globally for the diagnosis and treatment of HHT. Dr. F…

Bevacizumab (Avastin) Use In HHT

Policy Statement – 2020

Hereditary hemorrhagic telangiectasia (HHT, also known as OslerWeber-Rendu Syndrome) is a condition that is characterized by focal proliferation of blood vessels (vascular malformations) in multiple organs. Two of the most commonly affected organs in…

Bevacizumab for treating HHT patients with severe hepatic involvement or refractory anemia

Scientific Literature – 2020

PLoS One. Authors: Carolina Vázquez, María Laura Gonzalez, Augusto Ferraris, Juan Carlos Bandi, and Marcelo Martín Serra. This article is available for public use and does not require purchase. Click to view the full article.

The Science Behind the 2019 Scientific Conference (recorded)

Webinar – 2020

Philippe Marambaud, PhD and Andy White, MD discuss important advances in HHT research which were presented at the 2019 HHT International Scientific Conference in Puerto Rico. Learn about advancements in drug therapies for bleeding, screening and trea…

Orphanet-Journal-of-Rare-Diseases-Future-treatments-for-HHT

Future Treatments for Hereditary Hemorrhagic Telangiectasia

Scientific Literature – 2020

Orphanet Journal of Rare Diseases. Authors: Florian Robert, Agnès Desroches-Castan, Sabine Bailly, Sophie Dupuis-Girod and Jean-Jacques Feige. This article is available for public use and does not require purchase. Click to view the full article.

Systemic bevacizumab for high-output cardiac failure in HHT: an international survey of HHT centers

Scientific Literature – 2019

Orphanet Journal of Rare Diseases. Authors: Hanny Al-Samkari, Hasan A. Albitar, Scott E. Olitsky, Marianne S. Clancy and Vivek N. Iyer. This article is available for public use and does not require purchase. Click to view the full article.

Systemic bevacizumab for the treatment of chronic bleeding in HHT

Scientific Literature – 2018

Journal of Internal Medicine. Authors: Al-Samkari, H., Kritharis, A., Rodriguez-Lopez, J.M., and Kuter, D.J. This article can be purchased directly from the publisher. Click to view the article description and purchase options.

Endoglin Interacts with VEGFR2 to Promote Angiogenesis

Scientific Literature – 2018

The FASEB Journal. Authors: Hongyu Tian, Jennifer J. Huang, Christelle Golzio, Xia Gao, Melissa Hector-Greene, Nicholas Katsanis, and Gerard C. Blobe. This article is available for public use and does not require purchase. Click to view the full arti…

Endoglin Interacts with VEGFR2 to Promote Angiogenesis

Scientific Literature – 2018

Angiogenesis is the physiologic process by which new blood vessels arise from pre-existing vessels. Endoglin, a TGF-β coreceptor predominantly expressed in endothelial cells, plays an important role in vascular development and tumor-associated angiog…

HHT: Diagnosis and Management from the Hematologist’s Perspective

Scientific Literature – 2018

Haematologica. Authors: Athena Kritharis, Hanny Al-Samkari, and David J Kuter. This article is available for public use and does not require purchase. Click to view the full article.